Peroxiredoxin-1, a TLR4 ligand, has been shown to interact with TLR4 to promote prostate tumor cell growth through chronic activation of cancer angiogenesis in a murine cancer model (67). This evidence concerns the gene TLR4 and prostate neoplasm.